Felix Schmidt
Ludwig Maximilian University of Munich
27 Papers
66 Citations
Felix Schmidt is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Chemistry & Protein aggregation. The author has an hindex of 14, co-authored 23 publications.
Chat about Author
Papers
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
Jens Wagner,Sergey Ryazanov,Sergey Ryazanov,Andrei Leonov,Andrei Leonov,Johannes Levin,Song Shi,Felix Schmidt,Catharina Prix,Francisco J Pan-Montojo,Uwe Bertsch,Gerda Mitteregger-Kretzschmar,Markus Geissen,Martin Eiden,Fabienne Leidel,Thomas Hirschberger,Andreas A. Deeg,Julian J. Krauth,Wolfgang Zinth,Paul Tavan,Jens Pilger,Jens Pilger,Markus Zweckstetter,Markus Zweckstetter,Markus Zweckstetter,Tobias Frank,Mathias Bähr,Jochen H. Weishaupt,Manfred Uhr,Henning Urlaub,Henning Urlaub,Ulrike Teichmann,Matthias Samwer,Kai Bötzel,Martin H. Groschup,Hans A. Kretzschmar,Christian Griesinger,Christian Griesinger,Armin Giese +38 more
TL;DR: The findings suggest that pathological oligomers in neurodegenerative diseases share structural features, although the main protein component is disease-specific, indicating that compounds such as anle138b that modulate oligomer formation by targeting structure-dependent epitopes can have a broad spectrum of activity in the treatment of different protein aggregation diseases.
385
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset
Johannes Levin,Felix Schmidt,Cathrin Boehm,Catharina Prix,Kai Bötzel,Sergey Ryazanov,Andrei Leonov,Christian Griesinger,Armin Giese +8 more
TL;DR: These findings support the belief that blocked formation and accumulation of asyn oligomers in the brain, reduced disease-associated motor deficits, and led to prolonged disease-free survival in parkinson’s disease.
Cardiolipin promotes pore-forming activity of alpha-synuclein oligomers in mitochondrial membranes.
Stephanie Ghio,Angelique Camilleri,Mario Caruana,Viktoria Ruf,Felix Schmidt,Andrei Leonov,Sergey Ryazanov,Christian Griesinger,Ruben J. Cauchi,Frits Kamp,Armin Giese,Neville Vassallo +11 more
TL;DR: The formation of ion-permeable pores by αS oligomers in planar lipid bilayers reflecting the complex phospholipid composition of mitochondrial membranes was probed to preserve mitochondrial membrane integrity and alleviate mitochondrial dysfunction in PD.
85
[ 11 C]MODAG-001-towards a PET tracer targeting α-synuclein aggregates
Laura Kuebler,Sabrina Buss,Andrei Leonov,Sergey Ryazanov,Felix Schmidt,Andreas Maurer,Daniel Weckbecker,Anne M. Landau,Thea P. Lillethorup,Daniel Bleher,Ran Sing Saw,Bernd J. Pichler,Christian Griesinger,Armin Giese,Kristina Herfert +14 more
TL;DR: In this paper, a target-specific tracer to detect pathological aggregates of α-synuclein (αSYN) remains lacking, and a positron emission tomography (PET) tracer based on anle138b, a compound shown to have therapeutic activity in animal models of neurodegenerative diseases.
Polyphenolic compounds are novel protective agents against lipid membrane damage by α-synuclein aggregates in vitro.
Mario Caruana,Johanna Neuner,Johanna Neuner,Tobias Högen,Felix Schmidt,Frits Kamp,Charles Scerri,Armin Giese,Neville Vassallo +8 more
TL;DR: A group of polyphenols that can effectively hinder membrane damage by αS aggregates are identified and may serve as a viable source of lead compounds for the development and design of novel therapeutic agents in Parkinson's disease.
62